Here’s Why Supernus Pharmaceuticals (SUPN) Outperformed in Q3
Scout Investments, an affiliate of Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” third quarter 2022 investor letter. You can download a copy of the same here. The fund underperformed in the quarter relative to its Russell 2000 Growth Index benchmark. Macroeconomic headwinds affected the performance of the fund in the quarter. As per the letter, investors prefer growth stocks to value stocks, as small-cap growth stocks outperformed small-cap value stocks during the quarter. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.
Carillon Tower Advisers highlighted stocks like Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in its Q3 2022 investor letter. Based in Rockville, Maryland, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) operates as a biopharmaceutical company. On December 30, 2022, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stock closed at $35.67 per share. One-month return of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was -0.17%, and its shares gained 18.58% of their value over the last 52 weeks. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has a market capitalization of $1.928 billion.
Carillon Tower Advisers made the following comment about Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in its Q3 2022 investor letter:
“Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a biopharmaceutical company focused on developing and commercializing products for diseases of the central nervous system. Its new attention deficit/hyperactivity disorder (ADHD) product Qelbree is showing good growth with the label expansion approved for the adult ADHD market.”
Pressmaster/Shutterstock.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is not on our 30 Most Popular Stocks Among Hedge Funds list. As per our database, 21 hedge fund portfolios held Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) at the end of the third quarter, which was 19 in the previous quarter.
We discussed Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in another article and shared the best small-cap healthcare stocks to invest in. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors.
Suggested Articles:
Disclosure: None. This article is originally published at Insider Monkey.
